Annabelle Anandappa

ORCID: 0000-0003-4861-3159
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • T-cell and B-cell Immunology
  • Chronic Lymphocytic Leukemia Research
  • Nanoplatforms for cancer theranostics
  • Immune Cell Function and Interaction
  • Electrospun Nanofibers in Biomedical Applications
  • Tissue Engineering and Regenerative Medicine
  • Genetic factors in colorectal cancer
  • Cardiac Structural Anomalies and Repair
  • Erythrocyte Function and Pathophysiology
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Single-cell and spatial transcriptomics
  • Childhood Cancer Survivors' Quality of Life
  • DNA and Nucleic Acid Chemistry
  • Advanced biosensing and bioanalysis techniques
  • Cancer Research and Treatments
  • Pancreatic and Hepatic Oncology Research
  • Glioma Diagnosis and Treatment
  • Blood disorders and treatments

University of Cincinnati
2023-2024

Euroquality
2024

Harvard University
2018-2023

Dana-Farber Cancer Institute
2017-2023

Massachusetts General Hospital
2020-2021

Moscow Research and Clinical Center for Neuropsychiatry
2018

Columbia University
2013

Abstract Despite improvements in survival among pediatric patients with acute lymphoblastic leukemia (ALL), outcomes for adolescents and young adults (AYAs) ALL have lagged. The reasons the inferior AYAs are multifactorial, each presenting unique challenges requiring novel solutions. First, adverse disease biology is more common ALL. Ongoing trials investigating approaches to treatment, such as incorporating JAK inhibitors Philadelphia chromosome–like ALL, menin KMT2A-rearranged BCL2/BCLXL...

10.1182/hematology.2023000512 article EN Hematology 2023-12-08

2020 Background: The impact of individualized neoepitope vaccination targeting neoantigens arising from tumor-specific mutations for GBM, a low mutation burden tumor with an immunologically cold microenvironment, as well that concurrently administered dexamethasone (dex), are unknown. Methods: Individualized up to 20 synthetic, long peptides high predicted HLA binding affinity admixed poly-ICLC, were subcutaneously using prime-boost schedule after RT newly diagnosed, MGMT unmethylated, at...

10.1200/jco.2018.36.15_suppl.2020 article EN Journal of Clinical Oncology 2018-05-20

Abstract Personal vaccines directed at neoantigens arising from tumor mutations can induce neoepitope-specific T cell responses in patients with highly mutated tumors such as melanoma. It remains unknown if this approach be successfully applied low mutation frequency. We conducted a phase 1/1b study to determine the safety and feasibility of patient-specific neoantigen-targeting vaccination newly diagnosed, methylguanine methyltransferase (MGMT) unmethylated glioblastoma, administered...

10.1158/1538-7445.am2018-5631 article EN Cancer Research 2018-07-01

Autoimmune hemolytic anemia (AIHA) results in red blood cell destruction by auto-antibodies directed against surface antigens and is rarely fatal. Here we describe a case of AIHA, refractory to both standard experimental therapies, complicated multiorgan failure, rapidly leading death.A 65 year-old man who presented with progressive dyspnea jaundice was found have anemia. Diagnostic work-up revealed positive direct antiglobulin test strong pan-reactive antibody the plasma reacting titer...

10.1111/trf.16513 article EN Transfusion 2021-05-27

Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients following its approval by the U.S. Food Drug Administration for treatment steroid-refractory acute graft-versus-host disease. Although there extensive experience using ruxolitinib patients with myeloproliferative neoplasms, biologic effects clinical implications dosing, tapering, discontinuation HCT are incompletely characterized. We...

10.1002/onco.13903 article EN The Oncologist 2021-07-17

Abstract Obtaining paired alpha- and beta-chain information of the T cell receptor (TCR) enables identification which TCR binds to a particular antigen, providing critical knowledge for understanding how tumor interacts with its immune microenvironment monitoring responses immunotherapy. We have developed rapid, cost-effective single-cell sequencing protocol (scTCRseq) that processes single cells flow sorted into 384-well plates. Exploiting added specificity provided by RNase H-dependent PCR...

10.1158/1538-7445.am2018-5387 article EN Cancer Research 2018-07-01

The impact of individualized neoepitope vaccination targeting neoantigens arising from tumor-specific mutations for GBM, a low mutation burden tumor with an immunologically cold microenvironment, as well that concurrently administered dexamethasone (dex), are unknown. Individualized up to 20 synthetic, long peptides high predicted HLA binding affinity admixed poly-ICLC, were subcutaneously using prime-boost schedule after RT newly diagnosed, MGMT unmethylated, at least partially resected,...

10.1093/neuonc/noy148.027 article EN Neuro-Oncology 2018-11-01

Abstract Recent advances in single cell T receptor (TCR) sequencing have allowed detailed analysis of TCRαβ pairs. However, efficient methods for probing the specificity discovered TCRs remain limited. We developed a streamlined approach cloning and expressing screening against candidate antigens. A key innovation was establishment plasmid library to encode all variable (V) regions TCR, from which any TCR interest can be assembled with only custom synthesis short CDR3 regions. reporter...

10.4049/jimmunol.200.supp.181.11 article EN The Journal of Immunology 2018-05-01
Erin Aakhus Matti Aapro Valerie Aarne Sarah Abaricia Susan Abbinanti and 95 more Ahmed Abdelfattah Ahmed Abdulsamad Gregory A. Abel Ibrahim Abu-Gheida Syed A. Abutalib Lucile L. Adams‐Campbell Alfredo Addeo Dan Aderka Adewale Adisa Ahmed Afifi José Carlos Miriam Ahlborn Jordi Rodón Michele Aieta Kathryn J. Aikin Al Rabadi Al Zoughbi Olusegun Isaac Alatise S. Al-Batran Brian M. Alexander Muneer J. Al‐Husseini Siraj M. Ali Marco Alifano Carmen J. Allegra Ian M. Allen Kathleen Allen Timothy A. Allen Julio Allo Teresa Alonso‐Gordoa Alonso-Ovies Almudena Katherine Alpaugh Winfried Alsdorf Humaid O. Al‐Shamsi Bernd Alt‐Epping Ivy Altomare T. Altoos María Palmira Alves Roda Amaria Jennifer All- Amengual Milan J. Anadkat Andrea Anampa-Guzmán Annabelle Anandappa Benjamin O. Anderson Ana Andrade Leonardo Araújo-Andrade Valérie André Christopher Andrews M. De Angelis Trevor E. Angell Maria K. Angelopoulou Martina Angi Vladimir Anisimov Mitchell S. Anscher Lowell Anthony Emmanuel S. Antonarakis Carlotta Antoniotti Pedro Antunes-Meireles Smith Apisarnthanarax María Valero Arbizu James Armitage Adeolu Arowolo Marisol Arroyo‐Hernández Ryan Ashkar Atalaia -Barbacena F. Aubin Mark M. Awad Kristin Ayers Jean-Pierre M. Ayoub B Ba Hideo A. Baba Nalan Babacan Joseph Bacani Peter B. Bach Jean–Baptiste Bachet Renata Báez-Saldaña Valentina Baez-Sosa Mohammad Hadi Bagheri Ming-Jun Bai William H. Bailey Dean F. Bajorin Meghan A. Baker Richard L. Bakst Ирина Балдуева Melita Balja Justin M. Balko Samuel Ballentine Richard Bambury Elena Bandieri Giuseppe Luigi Banna Frances K. Barg Victoria Barghout T. Barnes Angela Barrero C Cabañes R. Paredes Martinez

10.1002/onco.13987 article EN The Oncologist 2021-12-01
Coming Soon ...